DrugPatentWatch Database Preview

SINUVA Drug Profile

« Back to Dashboard

When do Sinuva patents expire, and when can generic versions of Sinuva launch?

Sinuva is a drug marketed by Intersect Ent Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-four patent family members in ten countries.

The generic ingredient in SINUVA is mometasone furoate. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

Summary for SINUVA

International Patents:	24
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	62
Patent Applications:	4,593
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SINUVA
DailyMed Link:	SINUVA at DailyMed

See drug prices for SINUVA

Pharmacology for SINUVA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Synonyms for SINUVA

(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione

(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate

(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

04201GDN4R

11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate

2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester

83919-23-7

9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)

919M237

A840685

AB2000407

AC-941

AC1L9AZS

AK163902

AKOS015994732

AN-15438

Asmanex

Asmanex HFA

Asmanex Twisthaler

BC228151

BDBM50148733

BPBio1_000424

BRD-K60640630-001-03-7

BRD-K60640630-001-11-0

BRN 4340538

BSPBio_000384

C07817

C27H30Cl2O6

CAS-83919-23-7

CCG-220572

CHEBI:47564

CHEMBL1161

CS-2389

D00690

Danitin

DSSTox_CID_3333

DSSTox_GSID_23333

DSSTox_RID_76981

DTXSID4023333

Ecural

Elocone

Elomet

Flumeta

HMS1569D06

HMS2096D06

HMS2235I14

HMS3713D06

HY-13693

KS-00000SPL

KS-1275

LAS 41002

M2354

MLS002153879

MolPort-003-849-257

Mometasone 17-(2-furoate)

mometasone 17-furoate

mometasone furancarboxylate

mometasone furoate

Mometasone furoate (JAN/USP)

Mometasone furoate [USAN:USP:JAN]

Mometasone Furoate Impurity G

MOMETASONE FUROATE MONOHYDRATE

Mometasone furoate, >=98% (HPLC)

Mometasone furoate, European Pharmacopoeia (EP) Reference Standard

Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material

Mometasone furoate, United States Pharmacopeia (USP) Reference Standard

Monovo

Nasonex

NCGC00016950-01

NCGC00179578-01

NCGC00179578-03

NCGC00179578-04

Nosorex

NSC-746171

NSC746171

Ovixan

Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-

Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-

Prestwick_924

Prestwick0_000572

Prestwick1_000572

Prestwick2_000572

Prestwick3_000572

Q-101380

Rimelon

s1987

Sch 32088

Sch-32088

SCHEMBL4568

SMR001233233

SPBio_002603

SR-01000841209

SR-01000841209-2

ST24048112

TL8005500

Tox21_110705

Tox21_110705_1

UNII-04201GDN4R

WOFMFGQZHJDGCX-ZULDAHANSA-N

ZINC3938677

US Patents and Regulatory Information for SINUVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No

International Patents for SINUVA

Country	Patent Number	Estimated Expiration
Australia	2009276505
European Patent Office	1605863
Canada	2518960
China	101189016
Canada	2732355
European Patent Office	2320832
European Patent Office	1871383

Supplementary Protection Certificates for SINUVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0548114	SPC/GB97/064	United Kingdom		PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
0112669	96C0002	Belgium		PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622